Anticancer research · 2014
Pemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal mesothelioma: retrospective analysis of six cases.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nakano Michitaka, Kusaba Hitoshi, Makiyama Akitaka, Ariyama Hiroshi, Arita Shuji, Oda Hisanobu, Esaki Taito, Takayoshi Kotoe, Uchino Keita, Tamura Shingo, Kumagai Hozumi, Iwama Eiji, Shirakawa Tsuyoshi, Mitsugi Kenji, Takaishi Shigeo, Akashi Koichi, Baba Eishi
Аннотация
BACKGROUND: Malignant peritoneal mesothelioma (PM) is an extremely rare disease. Pemetrexed and platinum have been used for advanced PM following malignant pleural mesothelioma (PLM). Because PM differs considerably from PLM in clinical features, the efficacy and safety of these therapies have yet to be established.
PATIENTS AND METHODS: Six Japanese patients with PM who had been treated with pemetrexed-based chemotherapy in four Institutions were retrospectively identified. Treatment response, progression-free survival, and overall survival were examined. Toxicities of therapy were also evaluated.
RESULTS: Three patients with mild ascites achieved clinical benefits (one with partial response and two with stable disease). Treatments with reduced cisplatin or carboplatin for patients with massive ascites were safely performed. Median PFS and OS were 7.2 and 13.1 months, respectively. Grade 3 hematological toxicities appeared in two patients with massive ascites.
CONCLUSION: Selection of chemotherapy based on the patient's condition, such as ascites, might be important for advanced PM.
PATIENTS AND METHODS: Six Japanese patients with PM who had been treated with pemetrexed-based chemotherapy in four Institutions were retrospectively identified. Treatment response, progression-free survival, and overall survival were examined. Toxicities of therapy were also evaluated.
RESULTS: Three patients with mild ascites achieved clinical benefits (one with partial response and two with stable disease). Treatments with reduced cisplatin or carboplatin for patients with massive ascites were safely performed. Median PFS and OS were 7.2 and 13.1 months, respectively. Grade 3 hematological toxicities appeared in two patients with massive ascites.
CONCLUSION: Selection of chemotherapy based on the patient's condition, such as ascites, might be important for advanced PM.